• Fresenius entered an exclusive development agreement with WuXi Biologics, securing options for up to 37 biosimilar candidates over the next decade.
• The deal could expand its marketed and pipeline portfolio from 29 to 66 molecules, targeting over €370 billion in originator sales.
• Selected programs will use fee-for-service payments, with Fresenius retaining exclusive global commercialization rights and full product economics.
• Manufacturing strategy remains under its control, including potential transfers of selected products to wholly owned mAbxience.
• Operating cash flow will fund the agreement without new financing; 2026 guidance and the existing 2030 Biopharma ambition remain unchanged.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2426078_en) on November 02, 2026, and is solely responsible for the information contained therein.